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http://dx.doi.org/10.1016/j.ccr.2012.08.016SUMMARYInflammation can promote or inhibit cancer progression. In this study we have addressed the role of the
proinflammatory cytokine thymic stromal lymphopoietin (TSLP) during skin carcinogenesis. Using condi-
tional loss- and gain-of-function mouse models for Notch and Wnt signaling, respectively, we demonstrate
that TSLP-mediated inflammation protects against cutaneous carcinogenesis by acting directly on CD4 and
CD8 T cells. Genetic ablation of TSLP receptor (TSLPR) perturbs T-cell-mediated protection and results in the
accumulation of CD11b+Gr1+ myeloid cells. These promote tumor growth by secreting Wnt ligands and aug-
menting b-catenin signaling in the neighboring epithelium. Epithelial specific ablation of b-catenin prevents
both carcinogenesis and the accumulation of CD11b+Gr1+ myeloid cells, suggesting tumor cells initiate
a feed-forward loop that induces protumorigenic inflammation.INTRODUCTION
For many years cancer has been regarded predominantly as
a cell autonomous process in which genetically transformed
cells propagate the development of malignant neoplasms.
However, today it is well established that tumor progression
requires complex interactions between neoplastic cells and the
host-derived stroma, including tumor-associated fibroblasts,
niche-defining cells, and vasculature. Of critical importance is
also the relationship between the tumor and the host immune
system. Originally, tumor-infiltrating immune cells were thought
to reflect the attempts of the immune system to eliminate cancer
cells. However, today a large body of evidence indicates that
malignant neoplasms can induce qualitatively distinct types of
inflammation that are protumorigenic (Coussens and Werb,
2002; Hanahan and Weinberg, 2011).
Cancer-associated inflammation frequently exhibits profiles
that promote both immune evasion and the growth of malignantSignificance
Inflammatory responses that promote or inhibit cancer devel
level. In this study we show that TSLP can induce antitumorige
the growth of b-catenin-dependent skin tumors. Ablation of
inflammatory profile, resulting in the accumulation of CD11b+
Wnts. These findings provide a mechanistic explanation regar
allergic disorders and demonstrate a tumor protective role for
which tumor-associated myeloid cells can promote tumor gro
Ccells. Tumors can evade T-cell-mediated clearance by skewing
the acquired immune response from cytotoxic Th1 to permissive
Th2 profiles (Aspord et al., 2007) or by inducing immunosup-
pressive regulatory T cells (Quezada et al., 2011). Tumors can
also co-opt cells of the innate immune system to become
constituents of the protumorigenic stroma. Notably, cells of
the myeloid lineage, such as macrophages (Allavena et al.,
2008) and neutrophils (Fridlender et al., 2009) can promote
tumor growth by a variety of mechanisms, depending on their
differentiation status. Furthermore, poorly defined immature
myeloid cells can foster tumor growth directly (Kowanetz
et al., 2010; Qian et al., 2011; Yang et al., 2011) or by acting
as myeloid-derived suppressor cells (Gabrilovich and Nagaraj,
2009).
These data demonstrate that tumor cells modulate both
acquired and innate arms of the immune system to form an
integral component of the tumor stroma. The molecular basis
for such immunomodulatory roles, however, is poorly defined,opment are qualitatively distinct at a cellular and molecular
nic inflammation by acting directly on T cells, which prevent
TSLP-mediated immune responses dramatically alters the
Gr1+ myeloid cells that promote tumor growth by secreting
ding the reduced risk of cancer in patients who suffer from
TSLP. Furthermore, we reveal an additional mechanism by
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TSLP Promotes Antitumor Inflammation in the Skinand it is unclear to what extent oncogenes/tumor suppressors
influence tumor development by such indirect mechanisms.
Mutations in the Notch signaling pathway are associated with
a variety of human cancers and indicate that Notch can func-
tion as either a tumor suppressor or an oncogene (Weng and
Aster, 2004). In the skin, conditional inactivation of Notch1 in
the mouse epidermis results in the development of basal/
squamous cell carcinoma after chemically induced carcinogen-
esis (Demehri et al., 2009; Nicolas et al., 2003; Proweller et al.,
2006), suggesting that Notch functions as a tumor suppressor
in this tissue. In accordance, loss-of-function mutations in
human Notch receptors correlate with cutaneous and lung squa-
mous cell carcinoma (Agrawal et al., 2011; Stransky et al., 2011;
Wang et al., 2011).
Factors acting downstream of Notch with respect to epithelial
malignancies remain to be fully elucidated. However, deletion of
Notch1 in the murine epidermis leads to elevated levels of acti-
vated b-catenin (Nicolas et al., 2003), which has been shown
to induce skin tumor formation and regulate the maintenance
of CD34+ cancer stem cells (Gat et al., 1998; Malanchi et al.,
2008). The tumor suppressor activity of Notch signaling in the
skin may therefore at least in part be due to negative regulation
of the Wnt/b-catenin pathway. Whether b-catenin accumulation
is due to cell autonomous deregulation or is mediated by cross-
talk between different cell populations is unclear, although there
is evidence for both mechanisms (Devgan et al., 2005; Kwon
et al., 2011; Sanders et al., 2009).
Conditional inactivation of both Notch1 and Notch2 in the
murine epidermis results in a chronic inflammatory condition
resembling a severe form of atopic dermatitis (AD) that occurs
as a consequence of elevated TSLP expression by keratinocytes
(Demehri et al., 2008; Dumortier et al., 2010). This cytokine has
been shown to affect a variety of cell types in the immune system
and as such is believed to play a role in allergic disorders,
including AD and asthma (Ziegler, 2010). Interestingly, elevated
TSLP has also been associated with progression of various
epithelial malignancies, including breast and pancreatic cancer
(De Monte et al., 2011; Olkhanud et al., 2011; Pedroza-Gonzalez
et al., 2011). In light of this, it is intriguing that loss of Notch in the
skin results in increased tumor susceptibility and elevated
expression of TSLP. It is presently unclear to what extent these
processes are linked, although elucidation of how they interact
may provide insight into how inflammation can exert either
anti- or protumorigenic effects.
In this study, we have delineated the role of TSLP-mediated
inflammation during skin tumorigenesis by using loss- and
gain-of-function approaches for Notch and Wnt signaling,
respectively.
RESULTS
Loss of TSLP Receptor Signaling in Notch Mutant Mice
Results in Cutaneous Malignancy
To determine the role of TSLP in cutaneous cancer associated
with loss of Notch signaling, mice carrying a K5CreERT transgene
and floxed alleles of both Notch1 and Notch2 receptors
(N1N2K5) were crossed with Tslpr/ mice, thus generating
Notch1lox/lox;Notch2lox/lox;K5CreERT;Tslpr/ mice (herein re-
ferred to as N1N2K5 TSLPR). This allowed us to conditionally480 Cancer Cell 22, 479–493, October 16, 2012 ª2012 Elsevier Inc.ablate Notch signaling in the epidermis in the absence of TSLPR
signaling and therefore to dissect the role of TSLP during chronic
inflammation in response to Notch ablation. Consistent with our
previous study, N1N2K5 mice developed an AD-like disease
within 5 weeks of skin-specific inactivation of Notch1 and
Notch2, characterized by the degeneration of hair follicles into
large cysts. N1N2K5 TSLPR mice also developed a severe skin
disorder characterized by hair follicle degeneration (Figures
1A–1B; Figures S1A–S1C available online). However, in these
mutants the cystic lesions could be broadly classified into
two subtypes: those lined by nonproliferative epithelial cells
consisting of 1–3 cell layers or larger lesions surrounded by
hyperproliferative Ki67+ epithelial cells (Figures 1B and 1C;
Figure S1A). The hyperproliferative cystic structures in N1N2K5
TSLPR mice frequently extended deep into the underlying
connective tissue of the dermis and were often visible on the
surface of the skin (Figures 1A and S1B). Pathological analysis
classified these hyperproliferative cysts as dysplastic lesions
resembling keratoacanthomas, relatively low-grade hair follicle
malignancies that can progress to invasive squamous cell
carcinomas. The severity of the phenotype in N1N2K5 TSLPR
animals was reflected in survival rates, as these mutants died
by day 60 post-gene-inactivation (Figure 1D), most likely
because of complications resulting from barrier dysfunction
and tumor burden (data not shown).
These data indicate that TSLPR signaling prevents tumor
formation in Notch-deficient skin. In support of this, injec-
tion of N1N2K5 mice with TSLP-neutralizing antibodies re-
sulted in tumor development in 60% of animals (Figure S1D),
thus confirming the tumor protective function of TSLP-TSLPR
interactions.
The Tumor Protective Effect of TSLP Is Mediated
by Hematopoietic Cells
The TSLPR is expressed by a variety of hematopoietic cells,
including T, B, and dendritic cells. We therefore speculated
that elevated levels of TSLP may elicit tumor protective immune
responses. To confirm this, we generated bone marrow (BM)
chimeras in which CD45.2 N1N2K5 hosts were reconstituted
with CD45.1 Tslpr/ BM prior to Notch inactivation. The recip-
rocal experiment was also performed, in which CD45.1 Tslpr+/+
BM was used to reconstitute CD45.2 N1N2K5 TSLPR mice (Fig-
ure 2A). In the former, TSLPR/ / N1N2K5 chimeras devel-
oped hyperproliferative dermal cysts, resembling the tumors
observed in N1N2K5 TSLPR mice upon ablation of Notch
signaling (Figure 2B). Conversely, N1N2K5 TSLPR mice recon-
stituted with Tslpr+/+ BM were protected from tumor formation
and instead developed the AD-like disease that occurs in
N1N2K5 animals (Figure 2B). These data confirm that TSLPR
signaling elicits antitumor responses in hematopoietic cells.
Ablation of TSLPR Signaling Alters the Inflammatory
Microenvironment in Notch-Deficient Skin
The impaired antitumor immune response elicited in N1N2K5
TSLPR mice could result from either a decreased dermal
inflammatory response and/or an altered inflammatory profile.
To discriminate between these possibilities, we analyzed the
inflammatory cells present in the dermis of both N1N2K5 and
N1N2K5 TSLPR mice by flow cytometry.
Figure 1. Loss of TSLPR Signaling in
Notch-Deficient Epidermis Leads to Tumor
Formation
(A) Representative images of N1N2 TSLPR
control, N1N2K5, and N1N2K5 TSLPR mice
50 days after neonatal deletion of Notch.
(B and C) Representative hematoxylin and eosin
(H&E) (B) and Ki67 (C) staining on dorsal skin
sections of mice shown in (A). Photomicrographs
in (B) are shown at different magnifications to
demonstrate the hyperproliferative layers sur-
rounding cysts (asterisks) in N1N2K5 TSLPR mice
compared to N1N2K5 animals. Dotted lines mark
lumen/cell border. Scale bars: 100 mm.
(D) Survival curve of N1N2 TSLPR (n = 15) and
N1N2K5 TSLPR (n = 27) mice. See also Figure S1.
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inactivation, the inflammatory response in N1N2K5 TSLPR
mice was reduced compared to N1N2K5 mutants (data not
shown). However, once the macroscopic phenotype was highly
overt at 4–5 weeks after Notch ablation, the proportion of dermal
CD45+ cells in both N1N2K5 and N1N2K5 TSLPR mice was on
average 5-fold higher compared to normal littermate controls
(Figure 2C). Thus, the inflammatory response in N1N2K5 and
N1N2K5 TSLPRmicewas quantitatively equivalent at the pheno-
typic endpoint.
Detailed phenotypic analysis of the dermal inflammatory
infiltrates revealed several changes between N1N2K5 and
N1N2K5 TSLPR mice, including alterations in the proportions
of CD117+ mast cells and B220+ B cells (Figure 2D). However,
the most striking differences were apparent in the T and myeloid
cell compartments. In N1N2K5 animals, the proportion of CD4+
and CD8+ T cells was 12.7% and 10.4%, respectively, whereas
in N1N2K5 TSLPR mice, the proportions were reduced on
average to 1.8% and 1.1% (Figure 2D). In addition, CD11b+Gr1+
myeloid cells constituted just 7.2% of dermal CD45+ cells in
N1N2K5 mice, whereas this population increased dramatically
to 36.7% upon ablation of TSLPR (Figure 2D).
Collectively, these data demonstrate that loss of TSLPR
signaling in Notch-deficient epidermis results in reduced propor-
tions of CD4+ and CD8+ T cells and increased infiltration of
CD11b+Gr1+ myeloid cells.Cancer Cell 22, 479–493,TSLPR Signaling in T Cells
Mediates Protection against Tumor
Formation
The observation that specific populations
of dermal inflammatory cells are altered
quantitatively upon ablation of TSLPR
signaling suggests that the cells respon-
sible for mediating tumor protection in
response to TSLP are likely to be within
these compartments. Therefore, to func-
tionally assess the role that specific cell
types play in TSLP-mediated tumor
protection, lethally irradiated N1N2K5
mice were reconstituted with Tslpr+/+
BM derived from different gene targeted
mice lacking specific hematopoietic celltypes (Figure 2E). In this system, the development of tumors after
Notch inactivation is a direct consequence of loss of a specific
hematopoietic population.
We initially determined the functional contribution of lymphoid
populations by reconstituting N1N2K5 mice with Rag2/;gc/
and Rag2/BM. In both cases, more than 90% of reconstituted
N1N2K5 mice developed tumors, indicating that the protective
cell type resided within the T or B cell compartment, not the
NK cell population (Figures 2F and S2A). Consistent with this,
78% of the mice in which NK cells were depleted by injection
of PK1.36 monoclonal antibody remained tumor free, and those
mice that did develop tumors presented only mild lesions (Fig-
ure S2B). To determine if B cells were required for tumor protec-
tion, we reconstituted N1N2K5 mice with Jh/ BM. In this
experiment, 83% of mice were resistant to tumor formation, indi-
cating that B cells do not mediate TSLPR-dependent tumor
protection and therefore suggesting that the critical cell type
resides within the T cell compartment (Figures 2F and S2A). In
support of this, antibody-mediated depletion of CD4+ and
CD8+ T cells resulted in tumor development in 83% of N1N2K5
mice (Figure S2C). To establish the role of T cells conclusively,
we reconstituted N1N2K5 mice with Cd4/ and Cd8a/ BM.
In this setting, the majority of mice reconstituted with Cd4/
BM were resistant to tumor formation (73%), whereas 74% of
Cd8a/ / N1N2K5 chimeras developed severe tumors
(Figures 2F and S2A). Taken together, these data demonstrateOctober 16, 2012 ª2012 Elsevier Inc. 481
Figure 2. CD8+ T Cells Are Required for TSLPR-Mediated Tumor Suppression
(A) Schematic depiction of experimental layouts. Lethally irradiated CD45.2 N1N2K5 (n = 14) and N1N2K5 TSLPR mice (n = 10) were transplanted with CD45.1
Tslpr/ BM and CD45.1 Tslpr+/+ BM, respectively, prior to ablation of Notch.
(B) Bar diagram summarizing the results of the experiments described in (A). Data represent the results of three independent experiments. N1N2 (n = 15) and
N1N2 TSLPR (n = 12) littermate controls were included.
(C) Bar diagram showing the proportion of CD45+ cells in the dermis of N1N2 TSLPR control, N1N2K5, and N1N2K5 TSLPR mice 4–6 weeks after deletion
of Notch.
(D) Bar diagram showing the proportions of CD45+ subpopulations present in the dermis of N1N2K5 and N1N2K5 TSLPRmice 4–6 weeks after deletion of Notch
and development of overt skin phenotypes. (C) and (D) Dermal cell infiltrates were quantified by flow cytometry; data represent the mean of five independent
experiments (mean ± SD; *p < 0.01; **p < 0.001).
(E) Schematic depiction of experimental layout. N1N2K5 and littermatemice were transplantedwith BM fromRag2/;gc/ (n = 12/9),Rag2/ (n = 12/11), Jh/
(n = 12/7), Cd4/ (n = 16/11), or Cd8a/ (n = 15/10) donors.
(F) Bar diagram summarizing the combined results of six independent BM transfer experiments as depicted in (E).
(G) PCR analysis of Db1-Jb1 TCR rearrangement performed on genomic DNA from CD8+ T cells isolated from lymph nodes (LN) or dermis (Der). Tail and thymus
were used as germline and rearranged controls, respectively. Bands corresponding to rearrangements containing Jb1.1-Jb1.5 are indicated. Additional bands
are nonspecific. See also Figure S2.
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TSLP Promotes Antitumor Inflammation in the Skinthat CD8+ T cells are required to mediate the tumor-protective
response elicited by TSLPR signaling. Consistent with this, anal-
ysis of TCR rearrangement in dermal CD8+ T cells isolated from
N1N2K5 mice revealed the predominance of Db1-Jb1.4 rear-
rangements, suggesting that the cytotoxic T cell response is
antigen specific (Figure 2G).
Previous studies have demonstrated that TSLP acts directly
on CD4+ (Al-Shami et al., 2005; Rochman et al., 2007) and
CD8+ (Rochman and Leonard, 2008) T cells during allergic
immune responses. Thus, to investigate whether CD8+ T cells
alone or T cells in general are sufficient for tumor protection,
adoptive transfer experiments were performed in which
N1N2K5 TSLPR mice were injected with different combinations
of WT CD4+ and/or CD8+ T cells (Figure 3A; Figure S3A). When
CD8+ or CD4+ T cells were transferred alone, the proportion of
recipients exhibiting tumor resistance was 65% and 90%,
respectively (Figure 3B). Chimeric mice that did develop tumors
upon transfer of CD4+ or CD8+ T cells showed reduced tumor
numbers and severity compared to control mice receiving either
PBS, CD11c+ dendritic cells, or B220+ B cells (Figures 3B and
S3B; data not shown). The level of protection conferred by
CD4+ T cells was surprising in light of the BM reconstitution
experiments described above, which indicated that CD4+
T cells are dispensable for tumor protection. However, flow cyto-
metric analysis indicated that adoptively transferred CD4+ T cells
induced the recruitment of host-derived CD8+ T cells, thus
restoring the protective cytotoxic response (Figure 3C). The
highest level of protection was observed when CD4+ and CD8+
T cells were administered together, as recipients in these cases
exhibited complete protection from tumor development (Fig-
ure 3B). Importantly, tumor protection did not occur as a con-
sequence of inefficient gene inactivation or counterselection of
Notch-deficient epidermal cells (Figures S3C and S3D).
The finding that the adoptive transfer of WT T cells can prevent
tumor formation in N1N2K5 TSLPR mice indicates that T cells
respond directly to TSLP and do not act in response to another
TSLP responsive cell type. Consistent with this, phosphoflow
cytometric analysis of pSTAT5 expression, which acts down-
stream of TSLPR ligation, revealed that only dermal CD4+ and
CD8+ T cells from N1N2K5 mice are pSTAT5+ (Figures 3D and
S3E). Interestingly, TSLPR signaling does not appear to be
required for T cell migration in vitro (Figure S3F), and thus it
seems likely that its tumor-protective effect is mediated via
increased T cell survival/proliferation and/or activation.
Finally, to determine if TSLP-responsive T cells could elicit
protection against preformed tumors, we adoptively transferred
CD4+ and CD8+ T cells into N1N2K5 TSLPR mice 2 weeks
post-gene-inactivation and assayed tumor development (Fig-
ure 3E). Strikingly, compared to control animals receiving either
CD11c+ dendritic cells or B220+ B cells, mice receiving both
CD4+ andCD8+ T cells exhibited complete tumor protection (Fig-
ure 3F). Thus, TSLP-responsive T cells have the capacity to
control preformed malignancies, at least during the early stages
of tumor progression.
CD11b+Gr1+ Myeloid Cells Promote Tumor
Development
As described above, a significant inflammatory component in
N1N2K5 TSLPR dermis is the CD11b+Gr1+ myeloid population,Cwhich correlates with tumor progression. To assess if CD11b+
Gr1+ myeloid cells promote tumor growth in N1N2K5 TSLPR
mice, we depleted Gr1+ cells by intraperitoneal injection of the
RB6.8C5 monoclonal antibody (Figure 4A). Depletion of Gr1+
cells was confirmed by flow cytometric analysis of both periph-
eral blood and dermal infiltrates (Figure 4B and data not shown),
and tumor progression was assessed by histology. As expected,
mice receiving isotype control antibody developed large cystic
tumors lined by hyperproliferative epithelial cells (Figures 4C
and 4D). In contrast, mice in which Gr1+ cells were depleted
developed smaller cysts that were predominantly lined by
epithelial cells 1–2 cell layers thick, and thus resembled the
phenotype observed in N1N2K5 mice (Figures 4C and 4D).
The above data indicated that CD11b+Gr1+ myeloid cells
perform a functional role in promoting tumor development.
This observation may reflect myeloid-derived suppressor cell
activity, in which antitumor T cell responses are suppressed, or
may be due to the promotion of tumor growth in a more direct
manner. To distinguish between these possibilities, we isolated
CD11b+Gr1+ myeloid cells from the tumor-associated microen-
vironment of N1N2K5 TSLPR mice and assessed their ability to
suppress T cell activation in vitro. We could not detect any
effect of CD11b+Gr1+ myeloid cells on the proliferation of either
CD4+ or CD8+ T cells (Figure 4E). Accordingly, depletion of
CD11b+Gr1+ cells did not result in an increase of dermal
T cells in N1N2K5 TSLPR mice (Table S1). These data therefore
suggest that the CD11b+Gr1+ population does not perturb T cell
responses but rather promotes tumor growth directly.
Tumor Formation in the Absence of TSLPR Signaling
Is b-Catenin Dependent
The macroscopic phenotype presented in N1N2K5 TSLPR
mice is reminiscent of extracolonic manifestations presented in
patients with familial adenomatous polyposis (FAP), in which
loss-of-function mutations in the APC gene result in constitutive
activation of the Wnt/b-catenin pathway (Jagelman, 1991).
Elevated b-catenin-mediated signaling is also implicated in a
variety of skin cancers (Gat et al., 1998; Malanchi et al., 2008).
The link between Wnt/b-catenin signaling and cancer therefore
prompted us to investigate the status of b-catenin in N1N2K5
TSLPR mice.
Immunohistochemistry (IHC) for active b-catenin was per-
formed on skin sections from N1N2K5, N1N2K5 TSLPR, and
N1N2 TSLPR control mice. In N1N2K5 TSLPR mutants, active
b-catenin was present in the majority of hyperproliferative cysts,
in contrast to N1N2K5 mice, where it was largely absent
(Figure 5A). These data suggest a role for b-catenin in the devel-
opment and/or maintenance of skin tumors in these animals.
To investigate whether b-catenin is functionally required for
tumor development, we generated Notch1lox/lox;Notch2lox/lox;
Ctnnb1lox/lox;K5CreERT Tslpr/ mice (hereafter N1N2bcatK5
TSLPR), in which Notch1, Notch2, and the b-catenin gene
(Ctnnb1) can simultaneously be deleted in the skin (Figures
S4A and S4B). Strikingly, ablation of b-catenin prevented the
formation of cystic tumors in N1N2bcatK5 TSLPR mice, estab-
lishing that tumor development in these animals is b-catenin
dependent (Figure 5B). Flow cytometric analysis of dermal
infiltrates in N1N2bcatK5 TSLPR mice revealed increased
infiltration of CD45+ cells compared to littermate control animals,ancer Cell 22, 479–493, October 16, 2012 ª2012 Elsevier Inc. 483
Figure 3. T Cells Are Sufficient to Mediate TSLP-Dependent Tumor Protection
(A) Schematic depiction of experimental layout. N1N2K5 TSLPR mice were transplanted with 107 CD45.1+ immune cells in the following combination: CD11c+
cells (n = 3), B220+ B cells (n = 8), CD4+ T cells (n = 14), CD8+ T cells (n = 16), and CD4+ andCD8+ T cells (n = 8). One N1N2K5 TSLPRmouse injected with PBSwas
included as a positive control in each experiment (n = 5).
(B) Bar diagram showing the results of the experiment described in (A). Data represent the results of five independent experiments.
(C) Representative flow cytometric analysis of dermal T cells in a N1N2K5 TSLPR mouse adoptively transferred with WT CD45.1 CD4+ T cells. (Left) Shows
proportions of CD4+ and CD8+ T cells in dermal inflammatory infiltrates. (Middle and Right) Shows contribution to CD4+ and CD8+ T cells by donor-derived
(CD45.1) cells respectively.
(D) Flow cytometric analysis of pSTAT5 expression in CD4+ and CD8+ T cells in the dermis of N1N2K5 andN1N2K5 TSLPRmice. Analysis was performed 5weeks
after Notch inactivation, when animals displayed an overt skin phenotype.
(E) Schematic depiction of experimental layout. Notch signaling was ablated in N1N2K5 TSLPR mice. Two weeks post-gene-inactivation, animals were
transplanted with 107 CD11c+ cells (n = 2), B220+ B cells (n = 3), or CD4+ and CD8+ T cells (n = 5) from CD45.1 donors.
(F) Bar diagram showing the combined results of two independent experiments (described in E).
See also Figure S3.
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Figure 4. CD11b+Gr1+ Myeloid Cells Promote Tumor Development in N1N2K5 TSLPR Mice
(A) Schematic depiction of experimental layout. N1N2K5 TSLPR mice (n = 11) and N1N2 TSLPR littermate controls (n = 8) were injected with aGr1 antibody
(RB6.8C5) to deplete Gr1+ myeloid cells. Administration of aGr1 was initiated 2 days prior to deletion of Notch (induced by five consecutive tamoxifen injections
starting at P30) and subsequently every 5 days after the final tamoxifen injection. IgG2b isotype control antibody was also administered to N1N2K5 TSLPR mice
(n = 4) and N1N2 TSLPR littermates (n = 2; data not shown). Analysis was performed 7 weeks after Notch inactivation.
(B) Representative flow cytometric analysis of CD11b+Gr1+ myeloid cells in the dermis of N1N2K5 TSLPR mice injected with IgG2b or aGr1 antibody.
(C) Representative H&E staining performed on dorsal skin sections of N1N2K5 TSLPRmice receiving IgG2b isotype control antibody (top) or aGr1 (bottom). Scale
bars: 400 mm.
(D) Bar diagram summarizing the results of the experiment described in (A). Data represent the results of three independent experiments.
(E) Bar diagram showing the results of in vitro T cell suppression assay. Immunosuppressive activity of myeloid cells was assayed by coculturing splenic C57BL/6
T cells with CD45+CD11b+Gr1+ cells isolated from tumor-bearing N1N2K5 TSLPR skin in the ratios indicated. Myeloid cell numbers were kept constant (3.63 104
cells/well), and T cell numbers were reduced appropriately to adjust the T cell:myeloid cell ratio. BrdU incorporation was determined by measuring absorbance
after 72 hr of coculture. Data represents the results of three independent experiments (mean ± SD).
See also Table S1.
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Figure 5. Tumor Formation in N1N2K5 TSLPR Mice Is b-Catenin Dependent
(A) Representative IHC staining for active b-catenin on skin sections from N1N2K5 TSLPR and N1N2K5 mice. Genotypes are indicated beside each image. (Left)
Shows low magnification image of N1N2K5 TSLPR skin. (Right) Show high magnification of epithelial cells lining degenerative cysts. Asterisks demarcate single
cysts; dotted lines mark lumen/cell border.
(B) Representative photographs and H&E staining of N1N2bcatK5 TSLPRmice and littermate controls 65 days after gene inactivation. In all experimental settings
gene inactivation was performed by five consecutive daily tamoxifen injections starting at day P6.
(C and D) Representative flow cytometric analysis of dermal CD4+ and CD8+ T cells (C) and CD11b+Gr1+ myeloid cells (D) in N1N2bcat TSLPR, N1N2K5,
N1N2bcatK5 TSLPR, and N1N2K5 TSLPR mice. Scale bars: 200 mm.
See also Figure S4.
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continued to elicit a chronic inflammatory response (Figure S4C).
Consistent with the absence of TSLPR, CD4+ and CD8+ T cells
represented less than 3% of dermal CD45+ cells (Figure 5C).
Importantly, serum levels of TSLP remained elevated despite
the loss of b-catenin (Figure S4D).
Interestingly, the accumulation of dermal CD11b+Gr1+ mye-
loid cells was impaired in N1N2bcatK5 TSLPR mice (Figure 5D),486 Cancer Cell 22, 479–493, October 16, 2012 ª2012 Elsevier Inc.indicating that the recruitment and/or development of this
population is independent of TSLP but dependent on epithe-
lial-specific Wnt/b-catenin signaling.
CD11b+Gr1+ Myeloid Cells Promote Tumor
Development by Provision of Wnt Ligands
Having established that b-catenin signaling is required for cuta-
neous tumor development in N1N2K5 TSLPR mice, we next
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TSLP Promotes Antitumor Inflammation in the Skinaddressed how increasedWnt signaling is mediated. Initially, we
determined if Wnt ligand expression was upregulated in N1N2K5
TSLPR mice by performing real-time PCR on whole skin. This
analysis revealed that compared to normal skin isolated from
N1N2 TSLPR mice, skin from N1N2K5 TSLPR mutants
displayed increased expression of a variety of Wnt ligands,
including Wnt3a, Wnt4, Wnt10a, and Wnt10b (Figure 6A). We
then addressed the cellular source of Wnts by performing real-
time PCR on fluorescence-activated cell sorting (FACS)-purified
cell populations isolated from tumor-bearing N1N2K5 TSLPR
dermis. For this analysis, we focused our attention on CD11b+
Gr1+myeloid cells, as these cells are required for tumor develop-
ment in N1N2K5 TSLPR mice and accumulate in the tumor
stroma. Wnt ligand expression was also assessed in tumor-
associated CD11b+Gr1- cells and fibroblasts isolated from
N1N2K5 TSLPR mice, as well as normal dermal fibroblasts iso-
lated from N1N2 TSLPR controls. Interestingly, all cell types
isolated from N1N2K5 TSLPR tumors exhibited increased
expression of Wnt ligands compared to normal dermal fibro-
blasts (data not shown). However, comparison of the different
tumor-associated populations demonstrated that the highest
levels of Wnt ligand expression were detected in CD11b+Gr1+
myeloid cells, particularly with respect toWnt3a, which exhibited
a 40-fold increase in expression compared to tumor-associated
fibroblasts (Figure 6B). To confirm that CD11b+Gr1+ myeloid
cells produced WNT3A protein, we performed immunofluores-
cent (IF) staining on skin sections isolated from N1N2K5 TSLPR
and N1N2K5 mice. Consistent with the gene expression anal-
ysis, WNT3A colocalized with Gr1+ myeloid cells, which were
frequently located in close proximity to epithelial tumor cells (Fig-
ure 6C). In N1N2K5 dermis, Gr1+ cells were only rarely detected,
although those that were present were also WNT3A+ (Figure 6C
and data not shown). We also analyzed WNT3a expression by
western blot in tumor-bearing and non-tumor-bearing regions
of N1N2K5 TSLPR skin and correlated this data with the propor-
tions of CD11b+Gr1+ myeloid cells present. Consistent with our
previous observations, the highest levels of WNT3a expression
were detected in tumor-bearing regions of skin containing high
proportions of CD11b+Gr1+ myeloid cells (Figure 6D; Figures
S5A–S5C). We also observed WNT3A expression in cystic
epithelial cells in both N1N2K5 and N1N2K5 TSLPR skin (Fig-
ure 6C; Figure S5B), indicating that CD11b+Gr1+ myeloid cells
are not the exclusive source of this protein.
These data suggest that the elevated Wnt/b-catenin signaling
observed in N1N2K5 TSLPR skin tumors is at least in part medi-
ated by CD11b+Gr1+ myeloid cells. To explore this possibility
further, we performed a coculture assay using a Tcf-luciferase
reporter cell line (Tcf-Luc) in conjunction with myeloid cells
and/or fibroblasts isolated from tumor-bearing N1N2K5 TSLPR
skin. Coculture with CD11b+Gr1+ cells or fibroblasts alone did
not induce luciferase activity in the Tcf-Luc cells. However,
when used in combination, CD11b+Gr1+ cells and tumor fibro-
blasts induced a significant 2.5-fold increase in luciferase
activity compared to Tcf-Luc cells cultured alone (Figure 6E),
indicating that these cells have the functional capacity to induce
Wnt/b-catenin signaling in neighboring cells. The requirement of
tumor-associated fibroblasts likely reflects the expression of
potentiating factors by these cells, as we observed markedly
increased expression of the Wnt-potentiator Periostin (POSTN)C(Malanchi et al., 2012) in the stroma of N1N2K5 TSLPR dermis
(Figure S5D).
Collectively, these data indicate that the accumulation of
CD11b+Gr1+ myeloid cells in N1N2K5 TSLPR mice results in
promotion of tumor growth by increased provision of Wnt
ligands. In support of this conclusion, depletion of CD11b+Gr1+
cells from the dermis of N1N2K5 TSLPR mice using the
RB6.8C5 antibody results in reduced nuclear b-catenin staining
in epidermal cysts (Figure S5E).
TSLPR Signaling Mediates Tumor Protection
in Notch-Independent Skin Cancers
We next sought to determine if TSLP signaling could mediate
tumor protection in other models of skin cancer in which
Notch expression/signaling is maintained in the epidermis. To
this end, we utilized Ctnnb1lox(ex3);K5CreERT mice (hereafter
bcatD3K5), in which constitutively active b-catenin can be
induced in the epidermis by conditionally deleting exon3 of the
b-catenin gene (Harada et al., 1999). In this model, activation
of b-catenin results in the formation of hair-follicle-derived
tumors over a period of several months (Gat et al., 1998). We
subsequently generated bcatD3K5 mice lacking TSLPR
(bcatD3K5 TSLPR) and induced expression of the dominant
active mutant of b-catenin. In agreement with previous reports,
bcatD3K5 mice developed mild skin phenotypes at 75 days
post-gene-induction (Gat et al., 1998), presenting as cystic
hair-follicle-derived tumors (Figure 7A). In contrast, bcatD3K5
TSLPR mutants developed overtly more severe phenotypes
within 25 days of b-catenin induction, exhibiting extensive hair
loss and thickening of the skin (Figure 7A). When analyzed histo-
logically, cystic tumors were prevalent and were significantly
larger than those observed in bcatD3K5 mice (Figures 7A
and 7B), which at this time point had not developed a severe
skin phenotype. The difference in phenotypic severity between
the TSLPR-deficient and competent mice was reflected in
survival rates, with 80% of bcatD3K5 TSLPR animals succumb-
ing within 30 days of b-catenin induction. By contrast, all
bcatD3K5 mice survived beyond 60 days (Figure S6A). Impor-
tantly, TSLP serum levels were increased in both bcatD3K5
and bcatD3K5 TSLPR animals compared to littermate controls
(Figure 7C). Moreover, analysis of dermal inflammatory cells
revealed that CD4+ and CD8+ T cells were significantly reduced
in Tslpr/ compared to Tslpr+/+ control mutants (Figure 7D),
supporting the hypothesis that TSLP mediates protection from
cutaneous tumors by promoting T-cell-mediated immunity.
Interestingly, we also observed accumulating CD11b+Gr1+
populations in the cutaneous tumors arising in bcatD3K5 TSLPR
mice (Figure 7D). In this system b-catenin signaling is activated
in the epithelium autonomously and thus the effects of Wnt-
driven tumorigenesis should be independent of stromal derived
ligands. To confirm this, we depleted CD11b+Gr1+ cells in
bcatD3K5 TSLPR mice by intraperitoneal injection of RB6.8C5
and assessed tumor development upon gene activation. Consis-
tent with our hypothesis, tumor development in these animals
was not adversely affected by the depletion of Gr1+myeloid cells
(Figures S6B–S6D).
Taken together, these results suggest that TSLPR-
mediated inflammation protects against different forms of cuta-
neous tumors. In support of this conclusion, the accompanyingancer Cell 22, 479–493, October 16, 2012 ª2012 Elsevier Inc. 487
Figure 6. Tumor-Associated CD11b+Gr1+ Myeloid Cells Promote Tumor Development by Secreting Wnt Ligands
(A and B) Real-time PCR analysis for Wnt ligand expression performed on RNA isolated from whole-tumor-bearing N1N2K5 TSLPR skin (A) or specific cell
populations isolated from the tumor microenvironment (B). In (A) gene expression is expressed relative to whole skin isolated from N1N2 TSLPR controls. In (B)
gene expression is expressed relative to tumor-associated fibroblasts. Data represent the mean ± SD of three independent experiments.
(C) IF staining for Gr1, CD45, and WNT3a expression in the dermis of N1N2K5 and N1N2K5 TSLPR mice. Asterisks demarcate cyst lumen; dotted lines mark the
border between the cystic epithelium and the surrounding dermis. The image shown for N1N2K5 skin displays a region with extensive CD45 staining to
demonstrate the low proportions of Gr1+ cells. Scale bars: 100 mm.
(D) Western blot analysis of WNT3a expression in whole-skin extracts from nontumor and tumor-bearing regions of N1N2K5 TSLPR mice. Tubulin was used as
loading control; lanes shown are cropped from the same blot. The original blot is shown in Figure S5C.
(E) CD11b+Gr1+ and CD11b+Gr1- myeloid cells were isolated from tumor-bearing skin of N1N2K5 TSLPR mice and cocultured with 293T cells expressing a
Tcf-luciferase reporter (Tcf-Luc), with or without fibroblasts isolated from N1N2K5 TSLPR tumor-bearing skin (Tum Fibr) or WT dermis (WT Fibr). Luciferase
activity was measured 36 hr after coculture (mean ± SD).
See also Figure S5.
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Figure 7. TSLP Mediates Protection against b-Catenin-Dependent Skin Carcinogenesis
(A) Representative images of bcatD3K5 (n = 5) and bcatD3K5 TSLPR (n = 10) mice after induction of activated b-catenin by five consecutive daily injections of
tamoxifen starting at day P30. bcatD3 TSLPRmicewere used as normal littermate controls (n = 8). A bcatD3K5mouse is shown 75 days posttamoxifen to illustrate
accelerated tumor development in the absence of TSLPR signaling. H&E staining performed on dorsal skin sections from each mouse are shown below each
image. Arrows point to regions with overt skin phenotype. Scale bars: 100 mm.
(B) Bar diagram displaying the proportion of mice with the indicated skin phenotype 25 days after induction of activated B-catenin. Data represent the results of
three independent experiments.
(C) TSLP serum levels were measured in bcatD3K5 TSLPR (n = 5), bcatD3 TSLPR (n = 3), bcatD3K5 (n = 4), and N1N2K5 (n = 3) mice 3 weeks after b-catenin
activation or Notch inactivation at day P30. The bar diagram is the result of a single experiment run in triplicate (mean ± SD; *p < 0.05; **p < 0.001).
(D) Flow cytometric analysis of T cells and myeloid cells in the dermis of bcatD3 TSLPR control, bcatD3K5 TSLPR, and bcatD3K5 mice 30 days after induction of
activated bcatenin. All data are gated on CD45+ cells.
See also Figure S6.
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also demonstrates that TSLP-dependent immune responses
can protect against DMBA/TPA-induced tumors in a wild-type
background. Importantly, this model is independent of any
pre-existing genetic aberrations.
DISCUSSION
In this study, we have revealed a tumor protective role for the
cytokine TSLP during cutaneous skin cancer development.
This effect is primarily mediated by direct signaling on dermal
CD4+ andCD8+ T cells via the TSLPR, which prevents the growth
of b-catenin-dependent hair follicle tumors in Notch loss-
of-function and b-catenin gain-of-function mouse models.
Loss of TSLPR responsive T cells results in tumor development
and is accompanied by the induction of protumorigenic inflam-
mation, which augments Wnt/b-catenin signaling. These find-
ings reveal a tumor-protective role for TSLP and demonstrate
how acquired and innate arms of the immune system can
mediate pro- and antitumor effects. This in turn may have
broader implications with respect to the role of inflammation in
other epithelial malignancies.
TSLP and T-Cell-Mediated Tumor Protection
A key finding in this study is that direct activation of the TSLPR on
dermal TCRab+ T cells elicits antitumor immune responses
to cutaneous malignancies. The analysis performed in Notch
mutant mice indicates that both CD4+ and CD8+ T cells mediate
this protective effect, although CD8+ T cells are the essential
effector cells. That TSLP can mediate tumor protection by pro-
moting CD8+ T cell responses is surprising, as TSLP is consid-
ered to promote Th2-mediated immunity and thus is not normally
associated with cytotoxic responses (Liu et al., 2007). However,
it has been shown that TSLP can promote the development of
cytotoxic CD8+ T cells by inducing the differentiation of cytolytic
effectors that express IL-5 and IL-13 (Soumelis and Liu, 2004).
We also find that expression levels of IL-5 and IL-13 are elevated
in N1N2K5 dermis (Dumortier et al., 2010), suggesting that TSLP
induces a similar cytotoxic state in this model.
In addition, it appears likely that TSLP acts to maintain dermal
T cells, as their proportions are significantly reduced upon
TSLPR ablation. This is unlikely to be a consequence of impaired
homing as Transwell migration studies indicate that Tslpr/
T cells show normal migration (Figure S3F), consistent with
a previous report (He et al., 2008). Activation of dermal T cells
is also unaffected by loss of TSLPR (data not shown), suggesting
that activation-associated proliferation is not perturbed. It is
therefore likely that TSLP signaling promotes T cell survival by
acting directly on CD4+ and CD8+ T lymphocytes, as demon-
strated by earlier studies (Al-Shami et al., 2005; Rochman
et al., 2007; Rochman and Leonard, 2008).
Regardless of the precise mechanism, the data presented
here indicate that the tumor-protective role of TSLP is primarily
mediated by a direct effect on dermal T cells. In support of this
conclusion, the accompanying manuscript by Demehri et al.
(2012) also demonstrates that TSLP elicits antitumor T cell
immunity upon ablation of cutaneous Notch signaling. Interest-
ingly, in their model CD4+ T cells are sufficient for tumor protec-
tion andCD8+ T cells are dispensable. This is likely due to the use490 Cancer Cell 22, 479–493, October 16, 2012 ª2012 Elsevier Inc.of the Msx2-Cre deletor strain, which inactivates the Notch
pathway during development and thus primes the developing
immune system from an early time point. In our system, Notch
deletion is induced only after birth, meaning that any T cell
activity directed against epithelial tumor cells is a naive immuno-
logical response.
Induction of Protumorigenic Inflammation upon Loss
of TSLPR
An important consequence of TSLPR ablation in the mouse
models used in this study is the induction of protumorigenic
inflammation, an important functional component of which are
CD11b+Gr1+ myeloid cells. Why these cells accumulate in the
dermis of N1N2K5 TSLPR mice but only represent a relatively
minor population of myeloid cells in N1N2K5 animals is unclear
and needs further investigation. One possible explanation is
that the allergic response induced by TSLP is antagonistic to
protumorigenic components of the inflammatory milieu. Such
a mechanism has been proposed by a recent study indicating
that histamine produced during allergic immune reactions pre-
vents the accumulation of tumor-promoting immature CD11b+
Gr1+ myeloid cells (Yang et al., 2011). In addition, we cannot
formally exclude that the role of TSLP-responsive T cells is to
act directly against CD11b+Gr1+ myeloid cells. However, we
think this is unlikely based on the tumor-protective effect of
TSLP demonstrated in bcatD3K5 mice, where tumor develop-
ment occurs independently of myeloid cells.
An alternative explanation is that the CD11b+Gr1+ myeloid
cells are recruited by putative cancer stem cells (CSCs) that
secrete promyeloid factors. A recent study has demonstrated
that CD34+ cutaneous CSCs can induce a protumorigenic
stroma via paracrine effects (Beck et al., 2011). We also observe
expanded populations of immature CD34+ epithelial cells in the
tumors arising in N1N2K5 TSLPR mice (data not shown), sug-
gesting similar mechanisms may be operating in the models
used in this study.
Finally, it is possible that loss of TSLP-mediated immune
responses results in increased loads of pathogenic organisms
that may induce protumorigenic inflammation, as has been sug-
gested by the link between specific infections and carcinogen-
esis (Parkin, 2006).
Wnt-Dependent Tumor Promotion by CD11b+Gr1+
Myeloid Cells
The tumor-promoting role of CD11b+Gr1+ myeloid cells has
been reported previously by a variety of studies (Kowanetz
et al., 2010; Qian et al., 2011; Rodriguez and Ochoa, 2008).
Here, we demonstrate that these cells can exert this effect by
augmenting Wnt/b-catenin signaling in neighboring epithelial
cells via the secretion of Wnt ligands.
The ability of CD11b+Gr1+ myeloid cells to induce Wnt/
b-catenin signaling is dependent on tumor-associated fibro-
blasts, which probably reflects increased expression of the
Wnt potentiator POSTN. This suggests that the dermal stroma
in these mice is primed to facilitate the protumorigenic function
of CD11b+Gr1+ myeloid cells.
Because the recruitment of CD11b+Gr1+ cells is itself depen-
dent on elevated b-catenin expression in the epidermis, it is likely
that Wnt pathway activation is an early event during tumor
Cancer Cell
TSLP Promotes Antitumor Inflammation in the Skinprogression in the models described here. Indeed, loss of Notch
receptors can increase levels of nuclear b-catenin in a cell auton-
omous manner (Devgan et al., 2005; Kwon et al., 2011). There-
fore, we suggest that once recruited to the tumor stroma,
myeloid populations can augment the Wnt signaling cascade
and drive tumor growth. In this way, the epithelial population
that initiates cancer development establishes a feed-forward
loop that favors tumor progression.
Context-Dependent Role of TSLP during Cancer
Development
The central theme of this study is the tumor-protective effect of
TSLP during cutaneous cancer development. This is in contrast
to previous reports that find TSLP can promote tumor growth
and metastasis in mouse models of breast and pancreatic
cancer (De Monte et al., 2011; Olkhanud et al., 2011; Pedroza-
Gonzalez et al., 2011). The relevance of TSLP in this respect is
indeed highlighted by the fact that pharmaceutical companies
are seeking to develop drugs directed against TSLP (Edwards,
2008). However, within the human population, individuals who
suffer from atopic allergic disorders have a reduced risk of devel-
oping certain types of cancer (Gandini et al., 2005; Prizment
et al., 2007; Vajdic et al., 2009; Wang and Diepgen, 2005). It is
tempting to speculate that the context in which TSLP functions
as a tumor suppressor or tumor promoter is related to how
allergic immune responses affect barrier versus glandular
epithelial cells. It will be interesting to determine if TSLP-respon-
sive T cells that induce allergic inflammation in other barrier
epithelia, such as lung (Al-Shami et al., 2005), are also tumor
protective.
Thus, whether TSLP is inducing a pro- or antitumorigenic
immune response appears to be context- and tissue-dependent,
and therefore blocking TSLP-mediated responses as a potential




All animal work was conducted in accordance with Swiss national guidelines.
All mice were kept in the animal facility under EPFL animal care regulations.
They were housed in individual cages at 23C ± 1C with a 12 hr light/dark
cycle. All animals were supplied with food and water ad libitum. This study




K5CreERT, and Tslpr/ mice were previously described (Dumortier et al.,
2010). Notch1lox/lox;Notch2lox/lox;Tslpr/;K5CreERT mice were crossed
to Ctnnb1lox/lox (Malanchi et al., 2008) mice to generate Notch1lox/lox;
Notch2lox/lox; Ctnnb1lox/lox;Tslpr/;K5CreERT mice. Ctnnb1lox(ex3) mice
(Harada et al., 1999) were crossed with Tslpr/ mice and K5CreERT trans-
genic mice (Indra et al., 1999) to generate Ctnnb1lox(ex3);Tslpr/;K5CreERT
mice. C57BL/6 CD45.1 (B6.SJL-Ptprca/BoyAiTac) and Rag2/;gc/
(B6.Rag2tm1FwaIl2rgtmWjl) mice were purchased from Taconic Europe
(Germany). Tslpr/ and Rag2/ mice were crossed to C57BL/6 CD45.1
mice to obtain Tslpr/ CD45.1 and Rag2/ CD45.1 mice, respectively.
Jh/ (B6.129P2-Igh-Jtm1Cgn/J), Cd4/ (B6.129S2-Cd4tm1Mak/J), and
Cd8a/ (B6.129S2-Cd8atm1Mak/J) mice were purchased from the Jackson
Laboratory (Bar Harbor, ME, USA). All mice used as donors in the bonemarrow
chimera and adoptive transfer experiments were on a pure C57BL/6Cbackground. All Notch mutants were backcrossed >10 generations with
C57BL/6 mice and thus can be considered to be on a pure C57BL/6 back-
ground. Depending on the experiment, gene inactivation was achieved by
intraperitoneal injection at P6, P30, or P60 of control and floxed mutant mice
with 1 mg/20 g body weight of tamoxifen (Sigma-Aldrich, St. Gallen,
Switzerland) for five consecutive days.
Dermal Cell Isolation
Back skin was aseptically dissected from mice and incubated dermis-side
down in a 1 mg/ml solution of collagenase/dispase (Roche, Indianapolis,
IN, USA) for 1 hr at 37C. The dermis was separated from the epidermis, disso-
ciated mechanically, and incubated in a 2 mg/ml solution of collagenase
(Sigma-Aldrich) for 45 min at 37C with gentle agitation. Cell suspensions
were filtered through a 70 mm cell strainer (BD Falcon, Franklin Lakes, NJ,
USA) and washed twice in staining medium (13 HBSS/25 mM HEPES/2%
newborn bovine calf serum).
Flow Cytometry
Single-cell suspensions were stained with monoclonal antibody conjugates in
accordance with standard protocols and analyzed using a CyAn flow cytome-
ter (Dako, Glostrup, Denmark). Data analysis and processing was performed
using FlowJo software (Tree Star, Ashland, OR, USA).
Immunohistochemistry and Immunofluorescence
For immunohistochemistry, tissues were fixed in 4% PFA and embedded
in paraffin. After sectioning, 4 mm sections were rehydrated, blocked with
3% H2O2, and incubated in antigen retrieval buffer (10 mM Tris/1 mM
EDTA/0.05% Tween 20 [pH 9.0]) at 95C for 20 min. Sections were then
stained using unconjugated primary antibodies and the appropriate HRP-
conjugated secondary antibodies. Staining was revealed by DAB (Sigma-
Aldrich) revelation. For immunofluorescence, tissues were embedded in
OCT compound and frozen. Cryosections (8 mm) were then fixed in acetone
at 4C for 2 min and air-dried for 20 min. After rinsing in PBS, sections
were stained with unconjugated primary antibodies and the appropriate
fluorophore-conjugated secondary antibodies. Fluorescent images were
acquired using an LSM700 confocal microscope (Zeiss, Oberkochen,
Germany).
See the Supplemental Experimental Procedures for further details.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2012.08.016.
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